We’re excited to announce that Fibronostics has completed the acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced laboratory services in the U.S.

This milestone strengthens our ability to support continued R&D, biomarker development, and innovation in MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease) diagnostics.

­

Why this matters:

• Stronger U.S. presence: Expanding laboratory infrastructure and operational expertise.

• Accelerated innovation: Boosting non-invasive diagnostics like our flagship platform, LIVERFASt™.

• Better partnerships: Creating new opportunities with pharma, healthcare systems, and payers.

• Global alignment: Meeting urgent needs in a therapeutic area, seeing rapid momentum with FDA approvals, major biopharma investments, and new treatment breakthroughs.

“With the acquisition of Stone Clinical Laboratories, Fibronostics is significantly expanding its U.S. capabilities. This positions us to accelerate innovation and strengthen collaborations across the ecosystem, as we address the growing global burden of MASH and MASLD.”

– Brock Smith, CEO of Fibronostics.

By combining Stone Clinical Laboratories’ operational depth with Fibronostics’ proprietary digital health platforms, we’re advancing toward a future where non-invasive testing is accessible, reliable, and globally scalable.